Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US FDA panel embraces GSK/HGS anthrax drug raxibacumab

This article was originally published in Scrip

Executive Summary

Human Genome Science, a subsidiary of GlaxoSmithKline, on 2 November had little difficulty convincing a US FDA panel of outside advisers to back approval of the company's experimental inhalational anthrax drug, raxibacumab.



Related Companies